In this study, the magnitude of inflammation achieved in patients with high IL-6 and CRP was directly related to the magnitude of the clinical benefits of using anti-IL-1 (51), confirming the role of inflammation in CAD. The gene discussed is IL1A; the disease is coronary artery disorder.